SpectraScience Announces Presentation of WavSTAT4 Clinical Results for the Diagnosis of Small Colorectal Cancer Polyps at UEG...

SpectraScience Announces Presentation of WavSTAT4 Clinical Results for the Diagnosis of Small Colorectal Cancer Polyps at UEGW

SAN DIEGO, CA-(Marketwired - Nov 1, 2016) - SpectraScience, Inc. (OTCQB: SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today that Dr. Noor Mohammed of Leeds University, Leeds England, presented clinical findings of the WavSTAT4 Optical Biopsy System at United European Gastroenterology Week (UEGW) On October 19th. The WavSTAT4 Optical Biopsy SystemR was once again found to exceed the clinical guidelines adopted by EU and US medical societies for the diagnosis of small and diminutive colorectal polyps during screening colonoscopies.

"This study once again underscores the clinical accuracy of the WavSTAT4 for diagnosing small polyps when used in colorectal cancer screening. Optical characterization of these polyps in real time is highly desired in order to permit the adoption of medical strategies that would avoid the cost of traditional pathology and prevent unnecessary polypectomies. Unlike image-based technologies that are consistently shown not to work adequately unless in the hands of experts and require complex human interpretations of the data, our system works equally well with clinicians of virtually all experience levels," said Michael Oliver, President and Chief Executive Officer of SpectraScience, Inc. "The data from Leeds, once gathered and completely analyzed is a key element in our application for a favorable determination from the National Institute of Health and Clinical Excellence (NICE) in the UK. We expect to have our package together for NICE adjudication in Q1 2017."

About SpectraScience, Inc.:

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. Protected by more than 30 patents in 28 countries, covering fundamental elements of the technology, the WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative patent protected technology for clinical use.

For more information:

Visit our web site www.spectrascience.com

Forward-Looking Statement for SpectraScience, Inc.

This news release contains forward-looking statements that involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

Contacts: Media and Investors: SpectraScience, Inc. Lowell Giffhorn, CFO Phone: (858) 847-0200 x2019 Email: lgiffhorn@spectrascience.com

SpectraScience (CE) (USOTC:SCIE)
Historical Stock Chart
From Dec 2024 to Jan 2025